In a world reshaped by COVID-19, Brexit, and other major supply-affecting developments, EU regulators have put addressing economic disruptions due to medicinal product shortages at the top of their agenda. Pharmaceutical companies operating on the EU market are well advised to closely monitor legal and regulatory developments and assess the footprint and security of their global supply chain. Continue reading

See all Member News